Evidence, not marketing. 40+ products · 298 retailers reviewed & tracked, 156 scored
PeptideClear UK

Named peptide stack · Sexual Health Peptides

Sexual Health Stack

The Sexual Health Stack pairs PT-141 (Bremelanotide, FDA-approved in the US for premenopausal HSDD as Vyleesi) with Kisspeptin (research compound under active UK clinical investigation at Imperial College London). UK regulatory status for both is research-tier outside of clinical trial enrolment.

PT-141 (Bremelanotide) Kisspeptin

Why researchers pair these compounds

PT-141 acts on central-nervous-system melanocortin receptors. Mechanism is CNS arousal modulation, distinct from peripheral vascular action of PDE5 inhibitors like sildenafil. FDA-approved as Vyleesi in the US for premenopausal Hypoactive Sexual Desire Disorder.

Kisspeptin sits upstream of the reproductive endocrine axis, regulating GnRH release. UK clinical-research lead is the Waljit Dhillo lab at Imperial College London with active trial work in HSDD and IVF triggering.

Both are not UK-licensed medicines outside of clinical trial settings.

Mechanism

PT-141 melanocortin-receptor agonism at CNS MC1R and MC4R. Kisspeptin agonism at hypothalamic KISS1R receptors, driving GnRH release and downstream LH and FSH from the pituitary.

Components

PT-141 (Bremelanotide)

Melanocortin agonist. FDA-approved in US as Vyleesi.

Encyclopedia entry

Kisspeptin

GnRH-axis regulator. Active UK clinical trial research at Imperial College London.

Encyclopedia entry

Who this is for

UK retailers stocking the components

See PeptideClear Trust Index →

Ranked by CoA Trust tier. Editorial commentary based on publicly available information. We take no commission, referral fee or payment from anyone listed here.

Buyers wanting the broadest catalogue of delivery formats (vials + pens + nasals + capsules + topicals) in the UK segment.

Direct Peptides UKCoA: weak / closed

Research peptide retailer (US parent, UK subdomain) · BPC-157 £11.46 to £189.22 (volume tiers per SKU)

UK-localised subdomain of US-headquartered Direct Peptides (trademark held by Aspire Labs, Texas). Broadest format coverage in the UK segment: lyophilised vials, pre-mixed pens, nasal-spray stacks, capsules, topical cosmetic peptides. 8 years trading (since ~2017). 20 percent first-order discount on dedicated /first-order/ page.

Frequently asked questions

Is PT-141 the same as Viagra?

No. Different mechanism. PT-141 acts on CNS arousal pathways via melanocortin receptors. Sildenafil (Viagra) acts on peripheral vascular smooth muscle via PDE5 inhibition. Not interchangeable.

Can I get PT-141 on the NHS?

No. PT-141 is not UK-licensed. The US-approved Vyleesi has no UK marketing authorisation.

PeptideClear does not sell, dispense, prescribe, or recommend Sexual Health Stack for any specific person. This page is editorial commentary on the published preclinical literature and the UK retail landscape. Every research peptide on this page is sold under research-use-only framing.

Read our full methodology and how we are funded.

Last updated:
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). PeptideClear's editorial and publishing operation is delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates. Registered office: Cust Hall, Toppesfield, Halstead, Essex, CO9 4EB. Contact: hello@peptideclear.co.uk.

Standards and Governance

Operates under UK data protection and consumer standards, including UK GDPR.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.

Compare 298 UK retailers · Open the Trust Index